First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults

NCT07646353 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Malaria, Falciparum

Interventions

BIOLOGICAL: GSK4425689A SC
BIOLOGICAL: GSK4425689A IV
DRUG: Placebo

Sponsor

GlaxoSmithKline